Trial
NCT03342859
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Leiomyoma
Intervention
Vilaprisan, BAY1002670
Why stopped
Due to findings in the preclinical carcinogenicity studies for vilaprisan (BAY1002670)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-06